Committee for Medicinal Products for Human Use (CHMP) has recommended approval of MSD’s KEYTRUDA for two gynaecological ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...

Despite positive KEYNOTE-811 results, Merck & Co’s position in this setting is not devoid of threats from other competitors.

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...

In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.

EU CHMP recommends approval of Merck’s Keytruda regimens as treatment for patients with two types of gynaecologic cancers ...

Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a new indication. The regulatory body has now approved Keytruda in ...

Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated ...